A detailed history of Headlands Technologies LLC transactions in Eagle Pharmaceuticals, Inc. stock. As of the latest transaction made, Headlands Technologies LLC holds 1,674 shares of EGRX stock, worth $1,590. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,674
Holding current value
$1,590
% of portfolio
0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$3.71 - $6.07 $6,210 - $10,161
1,674 New
1,674 $6,000
Q1 2024

May 07, 2024

BUY
$4.26 - $6.51 $12,187 - $18,625
2,861 Added 75.69%
6,641 $34,000
Q4 2023

Feb 02, 2024

BUY
$4.63 - $15.21 $6,732 - $22,115
1,454 Added 62.51%
3,780 $19,000
Q3 2023

Nov 09, 2023

BUY
$15.21 - $22.88 $25,644 - $38,575
1,686 Added 263.44%
2,326 $36,000
Q2 2023

Aug 03, 2023

BUY
$17.74 - $31.87 $11,353 - $20,396
640 New
640 $12,000

Others Institutions Holding EGRX

About EAGLE PHARMACEUTICALS, INC.


  • Ticker EGRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 13,015,900
  • Market Cap $12.4M
  • Description
  • Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and in...
More about EGRX
Track This Portfolio

Track Headlands Technologies LLC Portfolio

Follow Headlands Technologies LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Headlands Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Headlands Technologies LLC with notifications on news.